China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2015
October 2015
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
Section I. Important Notice
Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any fictitious statements, misleading statements, or important omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third Quarter Report of the Company in person.
Yan Zhigang, person in charge of the Company, head of the accounting works Wei Pingxiao and Zhou Feifei, accounting body principals (accountant in charge) hereby confirm that the Financial Report of the Third Quarterly Report is authentic, accurate and complete.
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
Section II. Main accounting data and changes of shareholders I. Main accounting data and index
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting error correction or not
□Yes√ No
||||||||
|-|-|-|-|-|-|-|
||Current period-end||Period-end of last year||Increase/decrease||
|Total assets(RMB)|14,298,937,947.02||12,828,941,540.90||11.46%||
|Net assets attributable to|5,266,153,764.26||4,764,607,822.09||||
|shareholders of listed company|||||10.53%||
|(RMB)|||||||
|||||||Increase/decrease in|
|||Increase/decrease in|||||
|||||Year-begin to end of||comparison with year-|
||Current period|comparison with same|||||
|||||the Period||begin to Period-end of|
|||period of last year|||||
|||||||last year|
|Operating revenue (RMB)|6,866,003,376.77|9.30%||19,679,806,543.54||9.98%|
|Net profit attributable to|186,753,078.44|||574,072,330.77|||
|shareholders of the listed company||17.66%||||13.52%|
|(RMB)|||||||
|Net profit attributable to|||||||
|shareholders of the listed company|||||||
||183,019,662.66|20.67%||556,678,816.45||16.96%|
|after deducting non-recurring gains|||||||
|and losses(RMB)|||||||
|Net cash flow arising from||||408,159,149.92|||
||--|--||||169.26%|
|operating activities(RMB)|||||||
|Basic earnings per share|0.515|||1.583|||
|||17.58%||||5.74%|
|(RMB/Share)|||||||
|Diluted earnings per share|0.515|||1.583|||
|||17.58%||||5.74%|
|(RMB/Share)|||||||
|Weighted average ROE|3.61%|0.07%||11.46%||-2.03%|

 Items and amount of extraordinary profit (gains)/losses
√Applicable □Not applicable
In RMB
||||
|-|-|-|
|Item|Amount from year-begin to||
|||Note|
||end of the Period||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|||Mainly refers to the income of|
|||relocation compensation from|
|Gains/losses from the disposal of non-current asset (including the|||
||4,389,032.17|disposal of investment real estate|
|write-off that accrued for impairment of assets)|||
|||by subsidiary Sinopharm Holding|
|||Liuzhou|
|Governmental subsidy reckoned into current gains/losses (not|||
|||Mainly refers to the various|
|including the subsidy enjoyed in quota or ration according to|||
||13,640,742.24|specific grants and finance|
|national standards, which are closely relevant to enterprise’s|||
|||discount received in the Period|
|business)|||
|||Mainly because the bad debt of|
|||account receivable for Tibet Naqu|
|Reversal of impairment reserve for account receivable with|||
||3,273,444.33|Company, which has accrual|
|separate impairment testing|||
|||separately last year has collected|
|||in the Period|
|||Mainly due to the earnings from|
|||render a hosted services by|
|Income of trustee fee obtained from trust for management|375,000.00|Sinopharm Holding and China|
|||National Pharmaceutical Foreign|
|||Trade Corporation|
|||Mainly because subsidiary|
|||Sinopharm Holding Liuzhou|
|Other non-operating income and expenditure except for the|||
||2,864,911.21|obtained a relocation rewards and|
|aforementioned items|||
|||out-of-resettlement compensation|
|||due to the removal|
|Less: impact on income tax|5,055,519.61||
|Impact on minority shareholders’ equity (post-tax)|2,094,096.02||
|Total|17,393,514.32|--|

Concerning the extraordinary profit (gain)/loss defined byQ&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss inQ&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable√ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss inQ&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss.
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
II. Statement of the total shareholders and shares-held of top ten shareholders at end of the Period
1. Statement of the total common shareholders and shares-held of top ten common shareholders at end of the Period
In Share
||||||||
|-|-|-|-|-|-|-|
|Total common shareholders at|||||||
|||15,463|||||
|period-end|||||||
|Shares-held of top ten common shareholders|||||||
|||||Amount of|Number of share pledged/frozen||
||Nature of|Proportion of|Amount of shares||||
|Shareholders||||restricted shares|||
||shareholder|shares held|held||State of share|Amount|
|||||held|||
|Sinopharm GroupCo., Ltd.|State-ownedcorporate|51.00%|184,942,291|74,482,543|||
|National Councilfor SocialSecurity Fund –116|Domestic nonstate-ownedcorporate|2.29%|8,300,000||||
|China SecuritiesFinanceCorporationLimited|Domestic nonstate-ownedcorporate|2.12%|7,704,972||||
|National Councilfor SocialSecurity Fund –106|Domestic nonstate-ownedcorporate|2.01%|7,298,555||||
|HTHK/CMGFSGUFP-CMGFIRST STATECHINAGROWTH FD|Overseascorporate|1.94%|7,032,720||||
|VALUEPARTNERSCLASSIC FUND|Overseascorporate|1.61%|5,847,103||||
|CITIC Securities|Domestic nonstate-ownedcorporate|1.38%|5,007,937||||
|China LifeInsurance|Domestic nonstate-owned|1.17%|4,237,124||||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
|||||||
|-|-|-|-|-|-|
|Company Ltd.－tradition －general insuranceproducts -005L-CT001 Shen|corporate|||||
|New China LifeInsuranceCompany Ltd.－Dividend －individualbonuses -018L-FH002 Shen|Domestic nonstate-ownedcorporate|1.16%|4,199,772|||
|China SAFEInvestmentsLimited|Domestic nonstate-ownedcorporate|1.05%|3,804,400|||
|Particular about top ten common shareholders with un-restrict shares held||||||
|||||Type of shares||
|Shareholders||Amount of un-restrict common shares held||||
|||||Type|Amount|
|Sinopharm Group Co., Ltd.||110,459,748||RMB ordinary||
||||||110,459,748|
|||||shares||
|National Council for Social SecurityFund – 116||8,300,000||RMB ordinary||
||||||8,300,000|
|||||shares||
|China Securities FinanceCorporation Limited||7,704,972||RMB ordinary||
||||||7,704,972|
|||||shares||
|National Council for Social SecurityFund – 106||7,298,555||RMB ordinary||
||||||7,298,555|
|||||shares||
|HTHK/CMG FSGUFP-CMG FIRSTSTATE CHINA GROWTH FD||7,032,720||Domestically||
|||||listed foreign|7,032,720|
|||||shares||
|VALUE PARTNERS CLASSICFUND||5,847,103||Domestically||
|||||listed foreign|5,847,103|
|||||shares||
|CITIC Securities||5,007,937||RMB ordinary||
||||||5,007,937|
|||||shares||
|China Life Insurance Company Ltd.－tradition －general insuranceproducts -005L-CT001 Shen||4,237,124||||
|||||RMB ordinary||
||||||4,237,124|
|||||shares||
|New China Life Insurance CompanyLtd. －Dividend －individual||4,199,772||RMB ordinary||
||||||4,199,772|
|||||shares||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
|||||
|-|-|-|-|
|bonuses -018L-FH002 Shen||||
|China SAFE Investments Limited|3,804,400|RMB ordinary||
||||3,804,400|
|||shares||
|Explanation on associated|It is unknown that there exists no associated relationship or belongs to the consistent actionist|||
|relationship among the aforesaid|among the other tradable shareholders regulated by the Management Measure of Information|||
|shareholders|Disclosure on Change of Shareholding for Listed Companies.|||

Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement dealing in reporting period
□ Yes√ No
The shareholders of the Company have no buy-back agreement dealing in reporting period.
2. Total of shareholders with preferred stock held and the top ten shareholdings in Period-end
□Applicable √Not applicable
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial indexes as well as reasons
√ Applicable□Not applicable
1. Note receivable: cut down by 224.8243 million Yuan over that of opening balance with growth rate of-36.32%, mainly because the settlement service with trade acceptance reduced in the Period;
2. Other account receivable: increased 28.0236 million Yuan over that of opening balance with growth rate of98.07%, mainly because the deposit and margin are increased in the Period;
3. Other current assets: cut down by 16.1344 million Yuan over that of opening balance with growth rate of-40.03%, mainly because the VAT to-be-deducted reduced in the Period;
4. Interest payable: increased 2.1271 million Yuan over that of opening balance with growth rate of31.91%, mainly due to the rising financing scale in the Period;
5. Non-current liability due within one year: increased 3.0431 million Yuan over that of opening balance with growth rate of76.08%, mainly because corresponding fair value of the Member Points due within one year are increased over that of period-begin;
6. Long-term loans: increased 30.9984 million Yuan over that of opening balance with growth rate of78.09%, mainly due to the newly increased Pingshan Project loans in the Period;
7. Other business income: up 20.0843 million Yuan on y-o-y basis with growth rate of35.63%, mainly because the income from offeringR&D technical services and sales of material income increased;
8. Other business cost: up 16.3505 million Yuan on y-o-y basis with growth rate of145.50%, mainly because the sales material business goes up on y-o-y basis;
9. Non-operation income: dropped 19.8009 million Yuan on y-o-y basis with growth rate of-53.71%, mainly because in line with the litigation outcome last period, the compensation of lawsuit which accrual from previous years have been written back, and no such business occurred in the Period;
10. Non-operation expenditure: dropped 1.0394 million Yuan on y-o-y basis with growth rate of-67.56%, mainly because at same period of last year, there were poverty relief donations occurred while there is no such business in the Period;
11. Minority interest income: up 5.1862 million Yuan on y-o-y basis with growth rate of40.99%, mainly because the profitability upgrade in the Period;
12. Refunds of taxes: dropped 7.5003 million Yuan on y-o-y basis with growth rateof-83.83%, mainly because the tax refunds received in the Period declined;
13. Net cash flow arising from operation activities: up 997.5034 million Yuan on y-o-y basis with growth rate of169.26%, mainly because the purchase-to-pay and vary taxes paid in the Period declined on a y-o-y basis; 14. Cash paid for the purchase and construction of fixed assets, intangible assets and other long-term assets: dropped 90.5632 million Yuan on y-o-y basis with growth rateof-38.26%, mainly because the investment for construction work is decreased in the Period;
15. Net cash paid for the acquisition of subsidiaries and other business entities: up 7.8078 million Yuan on y-o-y
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
basis with growth rate of474.88%, mainly because the final equity payment for Sinopharm Holding Jiangmen is paid in the Period;
16. Net cash flow arising from investment activities: up 89.5344 million Yuan on y-o-y basis with growth rate of42.85%, mainly because the investment for construction work is decreased in the Period;
17. Cash received by investors: dropped 1928.7954 million Yuan on y-o-y basis with growth rateof-99.92%, mainly because at same period of last year, there is increased capital from private placement received while there is no such business occurred in the Period;
18. Cash received relating to other financing activities: dropped 32.1528 million Yuan on y-o-y basis with growth rateof-100%, mainly because the cash from downstream factoring business is received at same period of last year while there is no such business occurred in the Period;
19. Payment for debt: dropped 1062.2838 million Yuan on y-o-y basis with growth rateof-94.53%, mainly because the loans repaying in the Period decreased.
20. Net cash flow arising from financing activities: dropped 91,041.20 Yuan on y-o-y basis with growth rate of -116.92%, mainly because at same period of last year, there are increased capital from private placement received while there is no such business occurred in the Period;
II. Progress and influence of the main events as well as solution analysis specification
□Applicable√ Not applicable
III. Commitments made by the Company or shareholders holding above5% shares of the Company in reporting period or made in previous period and extending to reporting period√ Applicable□Not applicable
|||||||
|-|-|-|-|-|-|
||||Commitment|Commitment||
||||||Implementation|
|Commitments|Accepter|Contents||||
||||time|period||
|Share Merger||||||
|Reform||||||
|||As a large pharmaceutical commercial||||
|||enterprise whose business involves||||
|||pharmaceutical wholesale and retail,||||
|||Sinopharm Holding may overlap with the||||
|Commitments in||Company in geographical segmentation during||||
|report of|Sinopharm|its future business development. To avoid the||Long-term|Normally implement|
||||2005-06-21|||
|acquisition or|Holding|potential peer competition brought by such||effective||
|equity change||geographical overlap, Sinopharm Holding||||
|||undertakes that, upon the transfer of shares of||||
|||Sinopharm Holding Guangzhou it held to||||
|||Accord Pharma, “1. it will not newly-establish||||
|||or broaden within Guangdong any business||||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
|||||||
|-|-|-|-|-|-|
|||operation that actually compete with that of||||
|||Accord Pharma, or set up any new subsidiaries||||
|||or subordinate enterprises who engage in such||||
|||business. 2. it will enter into business||||
|||delineation with Accord Pharma and||||
|||Sinopharm Holding Guangzhou, thereby||||
|||giving the three parties clear geographical||||
|||areas to carry out pharmaceutical wholesale||||
|||and retail businesses, so as to avoid potential||||
|||peer competition. Apart from above,||||
|||Sinopharm Holding will no longer newly-||||
|||establish any enterprise that may compete with||||
|||Accord Pharma in the production and R&D of||||
|||pharmaceutical products.”||||
|Commitments in||||||
|assets||||||
|reorganization||||||
|||Sinopharm Holding has undertaken in the||||
|||Letter of Undertaking from Sinopharm Group||||
|||Co. Ltd. on Avoiding Peer Competition that, “I.||||
|||the Company and the enterprises it wholly-||||
|||owns, controls or has de facto control over||||
|||(excluding Sinopharm Accord and its||||
|||controlled enterprises, similarly hereinafter) do||||
|||not exist any business or operation that would||||
|||constitute substantive peer competition with||||
|||Sinopharm Accord and its controlled|||Controlling shareholder|
|||enterprises. II. the Company and the|||is implement in real|
|Commitments||enterprises it wholly-owns, controls or has de|||earnest, Sinopharm|
|make in initial|Sinopharm|facto control over will not engage in,||Long-term|Accord will actively|
||||2013-09-05|||
|public offering|Holding|participate in or carry out in Guangdong and||effective|urged the controlling|
|or re-financing||Guangxi any business or activities that would|||shareholder and actual|
|||constitute substantive competition with the|||controller to fulfill|
|||pharmaceutical commercial businesses of|||commitments|
|||Sinopharm Accord. III. the Company and the||||
|||enterprises it wholly-owns, controls or has de||||
|||facto control over will not engage in,||||
|||participate in or carry out any business or||||
|||activities that would constitute substantive||||
|||competition with the pharmaceutical industrial||||
|||businesses of Sinopharm Accord. IV. the||||
|||Company will not make use of its control over||||
|||Sinopharm Accord to damage the legal||||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||||
|-|-|-|-|-|
||interests of Sinopharm Accord and other||||
||shareholders (especially minority||||
||shareholders). The Letter of Undertaking takes||||
||effect since the date of issue and will remain||||
||effective during the entire period when the||||
||Company has been the controlling shareholder||||
||or connected party of Sinopharm Accord.||||
||During the validity of the Undertaking, the||||
||Company will indemnify in time Sinopharm||||
||Accord from any loss which may arise out of||||
||the Company’s violation of the Undertaking.”||||
||Sinopharm Holding has undertaken in the||||
||Letter of Undertaking from Sinopharm Group||||
||Co. Ltd. on Standardization of the Connected||||
||Transactions with China National Accord||||
||Medicines Corporation Ltd. that, “I. during the||||
||period when the Company takes control over||||
||Sinopharm Accord, the Company and the||||
||companies or enterprises it directly or||||
||indirectly controls (hereinafter referred to as||||
||“Connected Party”) will strictly standardize the||||
||connected transactions with Sinopharm Accord||||
||and its controlled enterprises. II. for those||||
||connected transactions beyond avoidance or|||Controlling shareholder|
||out of reasonable causes, the Company and|||is implement in real|
||Connected Party will enter into standardized|||earnest, Sinopharm|
|Sinopharm|connected transaction agreement with||Long-term|Accord will actively|
|||2013-09-05|||
|Holding|Sinopharm Accord according to law.||effective|urged the controlling|
||Sinopharm Accord will perform approval|||shareholder and actual|
||procedure according to relevant laws, rules and|||controller to fulfill|
||regulations, other standardization documents|||commitments|
||and its constitutional documents, and fulfill its||||
||obligation to disclose information on||||
||connected transactions. III. for those connected||||
||transactions beyond avoidance or out of||||
||reasonable causes, the Company and||||
||Connected Party will determine the prices of||||
||connected transactions based on the prices of||||
||same or similar transactions entered into by||||
||independent third parties of no connection||||
||while following the principles of open, fair and||||
||just to ensure the fairness. IV. when the board||||
||or shareholders’ meeting of Sinopharm Accord||||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||||
|-|-|-|-|-|
||votes on the relevant connected transactions||||
||involving the Company and other enterprises it||||
||controls, the Company will perform||||
||obligations including that necessary interested||||
||directors and shareholders shall be abstained||||
||from voting according to relevant regulations,||||
||and follow the legal procedures for approval of||||
||connected transactions and fulfill its||||
||information disclosure obligation. V. the||||
||Company guarantees to attend shareholders’||||
||meeting according to the constitutional||||
||documents of Sinopharm Accord, exercise its||||
||corresponding rights and assumed its||||
||corresponding obligations in an equitable||||
||manner, not to take advantage of its standing as||||
||controlling shareholder to seek unjust interests,||||
||or to use connected transactions to illegally||||
||transfer capital or profit out of Sinopharm||||
||Accord, or to prejudice the legal interests of||||
||Sinopharm Accord and other shareholders||||
||(especially minority shareholders). VI. the||||
||Letter of Undertaking takes effect since the||||
||date of issue and will remain effective during||||
||the entire period when the Company has been||||
||the controlling shareholder or connected party||||
||of Sinopharm Accord. During the validity of||||
||the Undertaking, the Company will indemnify||||
||in time Sinopharm Accord from any loss that||||
||may arise out of the Company’s violation of the||||
||Undertaking.”||||
||”Sinopharm Group has undertaken in the Letter||||
||of Undertaking from China National||||
||Pharmaceutical Group Corporation on|||Actual controller is|
||Avoiding the Peer Competition with China|||implement in real|
||National Accord Medicines Corporation Ltd.|||earnest, Sinopharm|
|Sinopharm|that, “I. in the coming five years, Sinopharm||Long-term|Accord will actively|
|||2013-10-16|||
|Group|Group intends to take appropriate measures||effective|urged the controlling|
||including replacement or acquisition of assets|||shareholder and actual|
||or equity reorganization to solve the problem of|||controller to fulfill|
||peer competition between Weiqida and|||commitments|
||Sinopharm Accord. II. apart from the matters||||
||disclosed in the past and in the Letter of||||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||||
|-|-|-|-|-|
||Undertaking, the Company and the enterprises||||
||it wholly-owns, controls or has de facto control||||
||over (excluding Sinopharm Accord and its||||
||controlled enterprises, similarly hereinafter) do||||
||not directly engage in, participate in or carry||||
||out within the PRC any business or activities||||
||that would constitute substantive competition||||
||with the production and operation of||||
||Sinopharm Accord. The relative undertakings||||
||in respect of avoiding peer competition given||||
||by the Company in the past remain valid. III.||||
||the Company will not take advantage of its||||
||control over Sinopharm Accord to damage the||||
||legal interests of Sinopharm Accord and||||
||other shareholders (especially minority||||
||shareholders). IV. the Letter of Undertaking||||
||takes effect since the date of issue and will||||
||remain effective during the entire period when||||
||the Company has been the de facto controller||||
||or connected party of Sinopharm Accord.”||||
||Sinopharm Group has undertaken in the Letter||||
||of Undertaking from China National||||
||Pharmaceutical Group Corporation on||||
||Standardization of the Connected Transactions||||
||with China National Accord Medicines||||
||Corporation Ltd that, “I. during the period||||
||when the Company takes control over||||
||Sinopharm Accord, the Company and the||||
|||||Actual controller is|
||companies or enterprises it directly or||||
|||||implement in real|
||indirectly controls (hereinafter referred to as||||
|||||earnest, Sinopharm|
||“Connected Party”) will strictly standardize the||||
|Sinopharm|||Long-term|Accord will actively|
||connected transactions with Sinopharm Accord|2013-09-22|||
|Group|||effective|urged the controlling|
||and its controlled enterprises. II. for those||||
|||||shareholder and actual|
||connected transactions beyond avoidance or||||
|||||controller to fulfill|
||out of reasonable causes, the Company and||||
|||||commitments|
||Connected Party will enter into standardized||||
||connected transaction agreement with||||
||Sinopharm Accord according to law.||||
||Sinopharm Accord will perform approval||||
||procedure according to relevant laws, rules and||||
||regulations, other standardization documents||||
||and its constitutional documents, and fulfill its||||
||obligation to disclose information on||||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|||connected transactions. III. for those connected|
|||transactions beyond avoidance or out of|
|||reasonable causes, the Company and|
|||Connected Party will determine the prices of|
|||connected transactions based on the prices of|
|||same or similar transactions entered into by|
|||independent third parties of no connection|
|||while following the principles of open, fair and|
|||just to ensure the fairness. IV. when the board|
|||or shareholders’ meeting of Sinopharm Accord|
|||votes on the relevant connected transactions|
|||involving the Company and other enterprises it|
|||controls, the Company will perform|
|||obligations including that necessary interested|
|||directors and shareholders shall be abstained|
|||from voting according to relevant regulations,|
|||and follow the legal procedures for approval of|
|||connected transactions and fulfill its|
|||information disclosure obligation. V. the|
|||Company guarantees not to take advantage of|
|||its standing as actual controller to seek unjust|
|||interests, or to use connected transactions to|
|||illegally transfer capital or profit out of|
|||Sinopharm Accord, or to prejudice the legal|
|||interests of Sinopharm Accord and other|
|||shareholders (especially minority|
|||shareholders).”VI. the Letter of Undertaking|
|||takes effect since the date of issue and will|
|||remain effective during the entire period when|
|||the Company has been the actual controller or|
|||connected party of Sinopharm Accord.|
|Other|||
|commitments to|||
|minority|||
|shareholders of|||
|the Company|||
|Completed on|||
||Yes||
|time or not|||

IV. Estimation of operation performance for year of 2015
Estimation on accumulative net profit from the beginning of the year to the end of next report period to be loss probably or the warning
of its material change compared with the corresponding period of the last year and explanation on reason
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
□ Applicable√ Not applicable
V. Particular about security investment
□ Applicable√ Not applicable
The Company had no security investment in Period.
VI. Equity of other listed company held by the Company
□ Applicable√ Not applicable
The Company has no equity of other listed company held at period-end
VII. Particulars about derivatives investment
□ Applicable√ Not applicable
The Company had no derivatives investment in Period.
VIII. Registration form of receiving research, communication and interview in the report period
□Applicable√ Not applicable
The Company has no research, communication and interview accepted in the Period
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
Section IV. Financial Statement
I. Financial statement
1. Consolidated Balance Sheet
Prepared by China National Accord Medicines Corporation Ltd.
2015-09-30
In RMB
||||
|-|-|-|
|Item|Closing balance|Opening balance|
|Current assets:|||
|Monetary funds|1,013,884,519.57|867,562,115.54|
|Settlement provisions|||
|Capital lent|||
|Financial assets measured by fair|||
|value and whose change is recorded in|||
|current gains and losses|||
|Derivative financial assets|||
|Notes receivable|394,171,131.23|618,995,440.09|
|Accounts receivable|8,338,293,189.08|7,018,312,673.19|
|Accounts paid in advance|93,893,147.30|96,043,154.40|
|Insurance receivable|||
|Reinsurance receivables|||
|Contract reserve of reinsurance|||
|receivable|||
|Interest receivable|||
|Dividend receivable|||
|Other receivables|56,598,493.86|28,574,927.90|
|Purchase restituted finance asset|||
|Inventories|2,490,715,532.51|2,322,333,262.87|
|Divided into assets held ready for|||
|sales|||
|Non-current asset due within one|||
|year|||
|Other current assets|24,174,145.31|40,308,591.47|
|Total current assets|12,411,730,158.86|10,992,130,165.46|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Non-current assets:|||
|Granted loans and advances|||
|Finance asset available for sales|||
|Held-to-maturity investment|||
|Long-term account receivable|||
|Long-term equity investment|162,956,577.03|157,604,846.85|
|Investment property|77,788,114.73|73,836,850.51|
|Fixed assets|775,007,642.63|745,557,829.35|
|Construction in progress|363,698,845.05|330,218,696.56|
|Engineering material|||
|Disposal of fixed asset|||
|Productive biological asset|||
|Oil and gas asset|||
|Intangible assets|139,853,402.48|144,383,753.87|
|Expense on Research and|||
||5,619,315.47|5,619,315.47|
|Development|||
|Goodwill|79,378,833.15|79,378,833.15|
|Long-term expenses to be|||
||38,413,747.56|39,154,232.03|
|apportioned|||
|Deferred income tax asset|80,430,122.44|85,146,479.50|
|Other non-current asset|164,061,187.62|175,910,538.15|
|Total non-current asset|1,887,207,788.16|1,836,811,375.44|
|Total assets|14,298,937,947.02|12,828,941,540.90|
|Current liabilities:|||
|Short-term loans|1,922,477,929.73|1,517,954,528.88|
|Loan from central bank|||
|Absorbing deposit and interbank|||
|deposit|||
|Capital borrowed|||
|Financial liability measured by fair|||
|value and with variation reckoned into|||
|current gains/losses|||
|Derivative financial liability|||
|Notes payable|1,419,083,464.80|1,468,166,640.64|
|Accounts payable|4,650,505,884.89|3,988,878,234.03|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Accounts received in advance|37,445,736.11|40,339,905.63|
|Selling financial asset of|||
|repurchase|||
|Commission charge and|||
|commission payable|||
|Wage payable|130,034,708.11|171,958,142.88|
|Taxes payable|96,380,767.63|77,445,669.46|
|Interest payable|8,793,790.26|6,666,712.19|
|Dividend payable|||
|Other accounts payable|334,100,084.70|412,347,201.51|
|Reinsurance payables|||
|Insurance contract reserve|||
|Security trading of agency|||
|Security sales of agency|||
|Divided into liability held ready|||
|for sale|||
|Non-current liabilities due within 1|||
||7,043,100.00|4,000,000.00|
|year|||
|Other current liabilities|||
|Total current liabilities|8,605,865,466.23|7,687,757,035.22|
|Non-current liabilities:|||
|Long-term loans|70,693,824.54|39,695,448.00|
|Bonds payable|||
|Including: preferred stock|||
|Perpetual capital|||
|securities|||
|Long-term account payable|10,822,806.36||
|Long-term wages payable|2,582,100.00|2,896,000.00|
|Special accounts payable|1,287,000.00|1,287,000.00|
|Accrual liabilities|||
|Deferred income|168,091,726.69|176,366,201.15|
|Deferred income tax liabilities|23,130,504.44|24,297,076.57|
|Other non-current liabilities|45,427,343.31|45,427,343.31|
|Total non-current liabilities|322,035,305.34|289,969,069.03|
|Total liabilities|8,927,900,771.57|7,977,726,104.25|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Owner’s equity:|||
|Share capital|362,631,943.00|362,631,943.00|
|Other equity instrument|||
|Including: preferred stock|||
|Perpetual capital|||
|securities|||
|Capital public reserve|1,863,894,533.34|1,863,894,533.34|
|Less: Inventory shares|||
|Other comprehensive income|||
|Reasonable reserve|||
|Surplus public reserve|181,315,971.50|181,315,971.50|
|Provision of general risk|||
|Retained profit|2,858,311,316.42|2,356,765,374.25|
|Total owner’s equity attributable to|||
||5,266,153,764.26|4,764,607,822.09|
|parent company|||
|Minority interests|104,883,411.19|86,607,614.56|
|Total owner’s equity|5,371,037,175.45|4,851,215,436.65|
|Total liabilities and owner’s equity|14,298,937,947.02|12,828,941,540.90|

 Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Zhou Feifei
2. Balance Sheet of parent company
In RMB
||||
|-|-|-|
|Item|Closing balance|Opening balance|
|Current assets:|||
|Monetary funds|213,025,111.81|257,173,314.81|
|Financial assets measured by fair|||
|value and whose change is recorded in|||
|current gains and losses|||
|Derivative financial assets|||
|Notes receivable|3,161,064.50|47,389,669.59|
|Accounts receivable|655,550,847.30|513,791,982.48|
|Accounts paid in advance|1,543,685.34|5,047,755.80|
|Interest receivable|1,929,700.38|1,890,165.10|
|Dividend receivable|||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Other receivables|1,506,696,764.87|1,111,423,809.76|
|Inventories|179,612,810.46|184,880,147.05|
|Divided into assets held ready for|||
|sales|||
|Non-current asset due within one year|||
|Other current assets|9,124,221.59|2,560,096.51|
|Total current assets|2,570,644,206.25|2,124,156,941.10|
|Non-current assets:|||
|Finance asset available for sales|||
|Held-to-maturity investment|||
|Long-term account receivable|||
|Long-term equity investment|2,777,356,071.41|2,772,004,341.23|
|Investment real estate|4,581,781.19|5,272,980.96|
|Fixed assets|94,108,637.37|17,175,509.65|
|Construction in progress|328,611,767.67|299,290,846.13|
|Engineering material|||
|Disposal of fixed asset|||
|Productive biological asset|||
|Oil and gas asset|||
|Intangible assets|35,949,262.39|36,923,545.12|
|Expense on Research and Development|||
|Goodwill|||
|Long-term expenses to be apportioned|7,756,920.48|5,681,186.10|
|Deferred income tax asset|2,860,992.26|2,800,803.02|
|Other non-current asset|51,539,700.38|68,103,087.93|
|Total non-current asset|3,302,765,133.15|3,207,252,300.14|
|Total assets|5,873,409,339.40|5,331,409,241.24|
|Current liabilities:|||
|Short-term loans|232,000,000.00|202,000,000.00|
|Financial liability measured by fair|||
|value and with variation reckoned into|||
|current gains/losses|||
|Derivative financial liability|||
|Notes payable|239,928,522.23|274,584,574.89|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Accounts payable|428,599,428.99|314,477,971.19|
|Accounts received in advance|2,857,671.39|322,008.81|
|Wage payable|16,387,574.14|20,339,767.52|
|Taxes payable|7,575,075.34|13,695,533.72|
|Interest payable|191,717.52|86,831.07|
|Dividend payable|||
|Other accounts payable|327,481,724.34|447,928,781.45|
|Divided into liability held ready|||
|for sale|||
|Non-current liabilities due within 1 year|||
|Other current liabilities|||
|Total current liabilities|1,255,021,713.95|1,273,435,468.65|
|Non-current liabilities:|||
|Long-term loans|65,693,824.54|39,695,448.00|
|Bonds payable|||
|Including: preferred stock|||
|Perpetual capital|||
|securities|||
|Long-term account payable|||
|Long-term wages payable|226,000.00|226,000.00|
|Special accounts payable|800,000.00|800,000.00|
|Accrual liabilities|||
|Deferred income|5,000,000.00|5,000,000.00|
|Deferred income tax liabilities|3,774,569.00|3,773,319.00|
|Other non-current liabilities|||
|Total non-current liabilities|75,494,393.54|49,494,767.00|
|Total liabilities|1,330,516,107.49|1,322,930,235.65|
|Owner’s equity:|||
|Share capital|362,631,943.00|362,631,943.00|
|Other equity instrument|||
|Including: preferred stock|||
|Perpetual capital|||
|securities|||
|Capital public reserve|1,869,692,921.70|1,869,692,921.70|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Less: Inventory shares|||
|Other comprehensive income|||
|Reasonable reserve|||
|Surplus public reserve|181,315,971.50|181,315,971.50|
|Retained profit|2,129,252,395.71|1,594,838,169.39|
|Total owner’s equity|4,542,893,231.91|4,008,479,005.59|
|Total liabilities and owner’s equity|5,873,409,339.40|5,331,409,241.24|

 3. Consolidated Profit Statement (this report period)
In RMB
||||
|-|-|-|
|Item|Current period|Prior period|
|I. Total operating income|6,866,003,376.77|6,281,963,971.53|
|Including: Operating income|6,866,003,376.77|6,281,963,971.53|
|Interest income|||
|Insurance gained|||
|Commission charge and commission|||
|income|||
|II. Total operating cost|6,641,799,761.77|6,100,229,470.64|
|Including: Operating cost|6,364,449,301.02|5,833,268,381.58|
|Interest expense|||
|Commission charge and commission|||
|expense|||
|Cash surrender value|||
|Net amount of expense of compensation|||
|Net amount of withdrawal of insurance|||
|contract reserve|||
|Bonus expense of guarantee slip|||
|Reinsurance expense|||
|Operating tax and extras|10,754,748.24|9,386,944.76|
|Sales expenses|131,702,711.01|112,238,970.55|
|Administration expenses|114,237,485.02|113,782,559.26|
|Financial expenses|20,199,936.13|29,944,760.23|
|Losses of devaluation of asset|455,580.35|1,607,854.26|
|Add: Changing income of fair value(Loss|||
|is listed with “-”)|||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Investment income (Loss is listed with|||
||11,264,688.74|13,143,999.51|
|“-”)|||
|Including: Investment income on|||
||11,264,688.74|13,143,999.51|
|affiliated company and joint venture|||
|Exchange income (Loss is listed with “-”)|||
|III. Operating profit (Loss is listed with|||
||235,468,303.74|194,878,500.40|
|“-”)|||
|Add: Non-operating income|4,081,386.64|8,528,482.74|
|Including: Disposal gains of non-|||
||417,021.63|191,595.79|
|current asset|||
|Less: Non-operating expense|58,358.45|330,963.49|
|Including: Disposal loss of non-current|||
||142,655.16|215,831.48|
|asset|||
|IV. Total Profit (Loss is listed with “-”)|239,491,331.93|203,076,019.65|
|Less: Income tax expense|47,223,465.50|40,074,573.40|
|V. Net profit (Net loss is listed with “-”)|192,267,866.43|163,001,446.25|
|Net profit attributable to owner’s of|||
||186,753,078.44|158,726,925.31|
|parent company|||
|Minority shareholders’ gains and losses|5,514,787.99|4,274,520.94|
|VI. Net other comprehensive income|||
|after-tax|||
|Net other comprehensive income after-|||
|tax attributable to owners of parent|||
|company|||
|(I) Other comprehensive income|||
|items which will not be reclassified|||
|subsequently to profit of loss|||
|1. Changes as a result of re-|||
|measurement of net defined benefit plan|||
|liability or asset|||
|2. Share of the other|||
|comprehensive income of the investee|||
|accounted for using equity method which|||
|will not be reclassified subsequently to|||
|profit and loss|||
|(II) Other comprehensive income|||
|items which will be reclassified|||
|subsequently to profit or loss|||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|1. Share of the other|||
|comprehensive income of the investee|||
|accounted for using equity method which|||
|will be reclassified subsequently to profit|||
|or loss|||
|2. Gains or losses arising|||
|from changes in fair value of available-|||
|for-sale financial assets|||
|3. Gains or losses arising|||
|from reclassification of held-to-maturity|||
|investment as available-for-sale financial|||
|assets|||
|4. The effect hedging portion|||
|of gains or losses arising from cash flow|||
|hedging instruments|||
|5. Translation differences|||
|arising on translation of foreign currency|||
|financial statements|||
|6. Other|||
|Net after-tax of other comprehensive|||
|income attributable to minority|||
|shareholders|||
|VII. Total comprehensive income|192,267,866.43|163,001,446.25|
|Total comprehensive income|||
||186,753,078.44|158,726,925.31|
|attributable to owners of parent Company|||
|Total comprehensive income|||
||5,514,787.99|4,274,520.94|
|attributable to minority shareholders|||
|VIII. Earnings per share:|||
|(i) Basic earnings per share|0.515|0.438|
|(ii) Diluted earnings per share|0.515|0.438|

 As for the business merger under the same control in the Period, Yuan net profit realized before merger by the combined party, the net profit for combined party in last period was Yuan.
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Zhou Feifei
4. Profit Statement of parent company (this report period)
In RMB
||||
|-|-|-|
|Item|Current period|Prior period|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|I. Operating income|707,895,452.73|734,321,077.76|
|Less: operating cost|673,918,156.37|705,436,495.45|
|Operating tax and extras|1,524,376.24|2,430,299.49|
|Sales expenses|11,228,666.13|12,365,596.47|
|Administration expenses|12,107,506.81|11,578,094.71|
|Financial expenses|-17,264,862.18|-30,454,474.94|
|Losses of devaluation of asset|116,627.27|116,740.12|
|Add: Changing income of fair|||
|value(Loss is listed with “-”)|||
|Investment income (Loss is listed with|||
||11,264,688.73|18,064,754.09|
|“-”)|||
|Including: Investment income on|||
||11,264,688.73|13,143,999.51|
|affiliated company and joint venture|||
|II. Operating profit (Loss is listed with|||
||37,529,670.82|50,913,080.55|
|“-”)|||
|Add: Non-operating income|234,465.95|10,044.48|
|Including: Disposal gains of non-|||
|current asset|||
|Less: Non-operating expense|-0.02||
|Including: Disposal loss of non-current|||
|asset|||
|III. Total Profit (Loss is listed with “-”)|37,764,136.79|50,923,125.03|
|Less: Income tax expense|6,429,993.21|7,900,592.86|
|IV. Net profit (Net loss is listed with|||
||31,334,143.58|43,022,532.17|
|“-”)|||
|V. Net after-tax of other comprehensive|||
|income|||
|(I) Other comprehensive income|||
|items which will not be reclassified|||
|subsequently to profit of loss|||
|1. Changes as a result of re-|||
|measurement of net defined benefit plan|||
|liability or asset|||
|2. Share of the other|||
|comprehensive income of the investee|||
|accounted for using equity method|||
|which will not be reclassified|||
|subsequently to profit and loss|||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|(II) Other comprehensive income|||
|items which will be reclassified|||
|subsequently to profit or loss|||
|1. Share of the othercomprehensive income of the investee|||
|accounted for using equity method|||
|which will be reclassified subsequentlyto profit or loss|||
|2. Gains or losses arising|||
|from changes in fair value of available-|||
|for-sale financial assets|||
|3. Gains or losses arisingfrom reclassification of held-to-maturityinvestment as available-for-salefinancial assets|||
|4. The effect hedging|||
|portion of gains or losses arising from|||
|cash flow hedging instruments|||
|5. Translation differences|||
|arising on translation of foreign|||
|currency financial statements|||
|6. Other|||
|VI. Total comprehensive income|31,334,143.58|43,022,532.17|
|VII. Earnings per share:|||
|(i) Basic earnings per share|||
|(ii) Diluted earnings per share|||

5. Consolidated profit statement (from year-begin to end of this period)
In RMB
||||
|-|-|-|
|Item|Current period|Prior period|
|I. Total operating income|19,679,806,543.54|17,894,606,405.81|
|Including: Operating income|19,679,806,543.54|17,894,606,405.81|
|Interest income|||
|Insurance gained|||
|Commission charge and commissio|n||
|income|||
|II. Total operating cost|19,001,427,483.59|17,322,455,843.61|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Including: Operating cost|18,166,110,341.44|16,460,036,038.82|
|Interest expense|||
|Commission charge and commission|||
|expense|||
|Cash surrender value|||
|Net amount of expense of compensation|||
|Net amount of withdrawal of insurance|||
|contract reserve|||
|Bonus expense of guarantee slip|||
|Reinsurance expense|||
|Operating tax and extras|37,198,437.99|36,859,658.29|
|Sales expenses|393,776,817.02|383,388,181.09|
|Administration expenses|317,826,858.37|330,858,718.45|
|Financial expenses|78,839,608.53|102,392,485.33|
|Losses of devaluation of asset|7,675,420.24|8,920,761.63|
|Add: Changing income of fair value(Loss|||
|is listed with “-”)|||
|Investment income (Loss is listed with|||
||39,538,750.18|36,739,722.01|
|“-”)|||
|Including: Investment income on|||
||39,538,750.18|36,739,722.01|
|affiliated company and joint venture|||
|Exchange income (Loss is listed with “-”)|||
|III. Operating profit (Loss is listed with|||
||717,917,810.13|608,890,284.21|
|“-”)|||
|Add: Non-operating income|17,063,676.10|36,864,548.07|
|Including: Disposal gains of non-|||
||427,318.99|692,585.33|
|current asset|||
|Less: Non-operating expense|499,038.83|1,538,460.84|
|Including: Disposal loss of non-current|||
||368,059.75|280,069.64|
|asset|||
|IV. Total Profit (Loss is listed with “-”)|734,482,447.40|644,216,371.44|
|Less: Income tax expense|142,572,320.00|125,875,954.02|
|V. Net profit (Net loss is listed with “-”)|591,910,127.40|518,340,417.42|
|Net profit attributable to owner’s of parent|||
||574,072,330.77|505,688,779.43|
|company|||
|Minority shareholders’ gains and losses|17,837,796.63|12,651,637.99|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||
|-|
|VI. Net other comprehensive income|
|after-tax|
|Net other comprehensive income after-|
|tax attributable to owners of parent|
|company|
|(I) Other comprehensive income|
|items which will not be reclassified|
|subsequently to profit of loss|
|1. Changes as a result of re-|
|measurement of net defined benefit plan|
|liability or asset|
|2. Share of the other|
|comprehensive income of the investee|
|accounted for using equity method which|
|will not be reclassified subsequently to|
|profit and loss|
|(II) Other comprehensive income|
|items which will be reclassified|
|subsequently to profit or loss|
|1. Share of the other|
|comprehensive income of the investee|
|accounted for using equity method which|
|will be reclassified subsequently to profit|
|or loss|
|2. Gains or losses arising|
|from changes in fair value of available-|
|for-sale financial assets|
|3. Gains or losses arising|
|from reclassification of held-to-maturity|
|investment as available-for-sale financial|
|assets|
|4. The effect hedging portion|
|of gains or losses arising from cash flow|
|hedging instruments|
|5. Translation differences|
|arising on translation of foreign currency|
|financial statements|
|6. Other|
|Net other comprehensive income after-|
|tax attributable to minority|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|VII. Total other consolidated income|591,910,127.40|518,340,417.42|
|Total consolidated income attributable to|574,072,330.77||
|||505,688,779.43|
|owners of parent company|||
|Total consolidated income attributable to|17,837,796.63||
|||12,651,637.99|
|minority shareholders|||
|VIII. Earnings per share:|||
|(i) Basic earnings per share|1.583|1.497|
|(ii) Diluted earnings per share|1.583|1.497|

 As for the business merger under the same control in the Period, Yuan net profit realized before merger by the combined party, the net profit for combined party in last period was Yuan.
6. Profit Statement of parent company (from year-begin to end of this period)
In RMB
||||
|-|-|-|
|Item|Current period|Prior period|
|I. Operating income|2,117,811,188.23|2,078,854,464.72|
|Less: operating cost|2,024,014,258.26|1,996,348,869.75|
|Operating tax and extras|4,266,591.00|6,249,456.18|
|Sales expenses|33,939,722.56|35,760,799.33|
|Administration expenses|34,245,121.31|36,834,667.09|
|Financial expenses|-49,584,705.81|-61,166,675.03|
|Losses of devaluation of asset|410,566.05|270,135.10|
|Add: Changing income of fair|||
|value(Loss is listed with “-”)|||
|Investment income (Loss is listed with|||
||554,051,869.71|498,608,841.32|
|“-”)|||
|Including: Investment income on|||
||39,538,750.18|36,739,722.01|
|affiliated company and joint venture|||
|II. Operating profit (Loss is listed with|||
||624,571,504.57|563,166,053.62|
|“-”)|||
|Add: Non-operating income|332,246.72|715,297.08|
|Including: Disposal gains of|||
|||326.59|
|non-current asset|||
|Less: Non-operating expense||0.08|
|Including: Disposal loss of non-current|||
|asset|||
|III. Total Profit (Loss is listed with “-”)|624,903,751.29|563,881,350.62|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Less: Income tax expense|17,963,136.37|16,251,065.83|
|IV. Net profit (Net loss is listed with “-”)|606,940,614.92|547,630,284.79|
|V. Net other comprehensive income|||
|after-tax|||
|(I) Other comprehensive income|||
|items which will not be reclassified|||
|subsequently to profit of loss|||
|1. Changes as a result of re-|||
|measurement of net defined benefit plan|||
|liability or asset|||
|2. Share of the other|||
|comprehensive income of the investee|||
|accounted for using equity method|||
|which will not be reclassified|||
|subsequently to profit and loss|||
|(II) Other comprehensive income|||
|items which will be reclassified|||
|subsequently to profit or loss|||
|1. Share of the other|||
|comprehensive income of the investee|||
|accounted for using equity method|||
|which will be reclassified subsequently|||
|to profit or loss|||
|2. Gains or losses arising|||
|from changes in fair value of available-|||
|for-sale financial assets|||
|3. Gains or losses arising|||
|from reclassification of held-to-maturity|||
|investment as available-for-sale|||
|financial assets|||
|4. The effect hedging|||
|portion of gains or losses arising from|||
|cash flow hedging instruments|||
|5. Translation differences|||
|arising on translation of foreign|||
|currency financial statements|||
|6. Other|||
|VI. Total comprehensive income|606,940,614.92|547,630,284.79|
|VII. Earnings per share:|||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||
|-|
|(i) Basic earnings per share|
|(ii) Diluted earnings per share|

7. Consolidated Cash Flow Statement (from year-begin to end of this period)
In RMB
||||
|-|-|-|
|Item|Current period|Prior period|
|I. Cash flows arising from operating|||
|activities:|||
|Cash received from selling commodities|||
||20,633,444,697.69|17,908,007,328.48|
|and providing labor services|||
|Net increase of customer deposit and|||
|interbank deposit|||
|Net increase of loan from central bank|||
|Net increase of capital borrowed from|||
|other financial institution|||
|Cash received from original insurance|||
|contract fee|||
|Net cash received from reinsurance|||
|business|||
|Net increase of insured savings and|||
|investment|||
|Net increase of amount from disposal|||
|financial assets that measured by fair|||
|value and with variation reckoned into|||
|current gains/losses|||
|Cash received from interest, commission|||
|charge and commission|||
|Net increase of capital borrowed|||
|Net increase of returned business capital|||
|Write-back of tax received|1,446,726.90|8,947,070.73|
|Other cash received concerning|||
||66,440,712.60|75,769,060.23|
|operating activities|||
|Subtotal of cash inflow arising from|||
||20,701,332,137.19|17,992,723,459.44|
|operating activities|||
|Cash paid for purchasing commodities|||
||19,119,988,676.85|17,447,751,970.38|
|and receiving labor service|||
|Net increase of customer loans and|||
|advances|||
|Net increase of deposits in central bank|||
|and interbank|||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Cash paid for original insurance|||
|contract compensation|||
|Cash paid for interest, commission|||
|charge and commission|||
|Cash paid for bonus of guarantee slip|||
|Cash paid to/for staff and workers|485,136,482.02|439,907,204.26|
|Taxes paid|441,876,457.82|421,428,798.02|
|Other cash paid concerning operating|||
||246,171,370.58|272,979,736.89|
|activities|||
|Subtotal of cash outflow arising from|||
||20,293,172,987.27|18,582,067,709.55|
|operating activities|||
|Net cash flows arising from operating|||
||408,159,149.92|-589,344,250.11|
|activities|||
|II. Cash flows arising from investing|||
|activities:|||
|Cash received from recovering|||
||0.00|0.00|
|investment|||
|Cash received from investment income|35,190,000.00|28,152,000.00|
|Net cash received from disposal of fixed,|||
||998,055.18|1,257,052.51|
|intangible and other long-term assets|||
|Net cash received from disposal of|||
||0.00|0.00|
|subsidiaries and other units|||
|Other cash received concerning|||
||0.00|0.00|
|investing activities|||
|Subtotal of cash inflow from investing|||
||36,188,055.18|29,409,052.51|
|activities|||
|Cash paid for purchasing fixed,|||
||146,167,376.75|236,730,564.01|
|intangible and other long-term assets|||
|Cash paid for investment|0.00|0.00|
|Net increase of mortgaged loans|||
|Net cash received from subsidiaries and|||
||9,452,000.00|1,644,172.91|
|other units|||
|Other cash paid concerning investing|||
||0.00|0.00|
|activities|||
|Subtotal of cash outflow from investing|||
||155,619,376.75|238,374,736.92|
|activities|||
|Net cash flows arising from investing|||
||-119,431,321.52|-208,965,684.41|
|activities|||
|III. Cash flows arising from financing|||
|activities|||
|Cash received from absorbing|1,470,000.00|1,930,265,413.47|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|investment|||
|Including: Cash received from absorbing|||
|minority shareholders’ investment by|1,470,000.00|0.00|
|subsidiaries|||
|Cash received from loans|125,722,354.87|174,372,388.34|
|Cash received from issuing bonds|||
|Other cash received concerning|||
||0.00|32,152,750.15|
|financing activities|||
|Subtotal of cash inflow from financing|||
||127,192,354.87|2,136,790,551.96|
|activities|||
|Cash paid for settling debts|61,469,731.00|1,123,753,511.67|
|Cash paid for dividend and profit|||
||154,678,884.00|183,572,083.63|
|distributing or interest paying|||
|Including: Dividend and profit of|||
|minority shareholder paid by|1,032,000.00|5,825,783.82|
|subsidiaries|||
|Other cash paid concerning financing|||
||42,818,773.74|50,827,980.27|
|activities|||
|Subtotal of cash outflow from financing|||
||258,967,388.74|1,358,153,575.57|
|activities|||
|Net cash flows arising from financing|||
||-131,775,033.87|778,636,976.39|
|activities|||
|IV. Influence on cash and cash|||
|equivalents due to fluctuation in|7,360.46|5,838.21|
|exchange rate|||
|V. Net increase of cash and cash|||
||156,960,154.94|-19,667,119.92|
|equivalents|||
|Add: Balance of cash and cash|||
||854,212,006.84|1,097,948,354.45|
|equivalents at the period -begin|||
|VI. Balance of cash and cash equivalents|||
||1,011,172,161.78|1,078,281,234.53|
|at the period -end|||

8. Cash Flow Statement of parent company (from year-begin to end of this period)
In RMB
||||
|-|-|-|
|Item|Current period|Prior period|
|I. Cash flows arising from operating|||
|activities:|||
|Cash received from selling commodities|||
||2,245,035,658.21|2,178,553,762.47|
|and providing labor services|||
|Write-back of tax received|0.00|0.00|
|Other cash received concerning|10,277,088.77|16,271,321.78|

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|operating activities|||
|Subtotal of cash inflow arising from|||
||2,255,312,746.98|2,194,825,084.25|
|operating activities|||
|Cash paid for purchasing commodities|||
||2,207,784,468.53|2,155,142,728.62|
|and receiving labor service|||
|Cash paid to/for staff and workers|43,554,714.68|39,046,375.47|
|Taxes paid|38,063,645.73|26,377,550.12|
|Other cash paid concerning operating|||
||15,519,036.73|21,802,894.06|
|activities|||
|Subtotal of cash outflow arising from|||
||2,304,921,865.67|2,242,369,548.27|
|operating activities|||
|Net cash flows arising from operating|||
||-49,609,118.69|-47,544,464.02|
|activities|||
|II. Cash flows arising from investing|||
|activities:|||
|Cash received from recovering|||
|investment|||
|Cash received from investment income|219,294,985.39|234,399,564.16|
|Net cash received from disposal of fixed,|||
|||700.00|
|intangible and other long-term assets|||
|Net cash received from disposal of|||
|subsidiaries and other units|||
|Other cash received concerning|||
||2,488,319,315.47|2,954,312,357.21|
|investing activities|||
|Subtotal of cash inflow from investing|||
||2,707,614,300.86|3,188,712,621.37|
|activities|||
|Cash paid for purchasing fixed,|||
||118,417,451.35|166,131,758.87|
|intangible and other long-term assets|||
|Cash paid for investment|0.00|8,110,000.00|
|Net cash received from subsidiaries and|||
||9,200,000.00|6,761,000.00|
|other units|||
|Other cash paid concerning investing|||
||2,883,936,599.67|4,008,433,743.73|
|activities|||
|Subtotal of cash outflow from investing|||
||3,011,554,051.02|4,189,436,502.60|
|activities|||
|Net cash flows arising from investing|||
||-303,939,750.16|-1,000,723,881.23|
|activities|||
|III. Cash flows arising from financing|||
|activities|||
|Cash received from absorbing|||
||0.00|1,930,265,413.47|
|investment|||

China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
||||
|-|-|-|
|Cash received from loans|94,933,328.85|58,095,448.00|
|Cash received from issuing bonds|||
|Other cash received concerning|||
||337,881,122.11|394,669,491.62|
|financing activities|||
|Subtotal of cash inflow from financing|||
||432,814,450.96|2,383,030,353.09|
|activities|||
|Cash paid for settling debts|10,000,000.00|945,000,000.00|
|Cash paid for dividend and profit|||
||82,413,625.11|88,630,556.66|
|distributing or interest paying|||
|Other cash paid concerning financing|||
||31,000,160.00|128,579,308.55|
|activities|||
|Subtotal of cash outflow from financing|||
||123,413,785.11|1,162,209,865.21|
|activities|||
|Net cash flows arising from financing|||
||309,400,665.85|1,220,820,487.88|
|activities|||
|IV. Influence on cash and cash|||
|equivalents due to fluctuation in||1,201.00|
|exchange rate|||
|V. Net increase of cash and cash|||
||-44,148,203.00|172,553,343.63|
|equivalents|||
|Add: Balance of cash and cash|||
||257,173,314.81|218,342,947.03|
|equivalents at the period -begin|||
|VI. Balance of cash and cash equivalents|||
||213,025,111.81|390,896,290.66|
|at the period -end|||

II. Audit report
Whether the third quarter report was audited or not
□Yes√No
The third quarter report of the Company has not been audited